Meet Our Board of Directors
Our Board of Directors has diverse experience in biotechnology, diagnostics, therapeutics, medical and other industries, bringing decades of experience to the team.
Mr. Posard brings over 30 years’ experience of general management and commercialization experience in the biotechnology and diagnostics industry. His expertise is introducing novel and transformational products to medical and research markets while scaling organizations efficiently. Mr. Posard has held executive title responsibilities with several highly successful growth companies including Illumina, Biosite and Gen-Probe. From 2006 to 2015, he held executive positions at Illumina as its VP of Marketing, VP Global Sales and then as Senior VP, General Manager of its Translational and Consumer Genomics and New and Emerging Markets business units. Mr. Posard currently serves on multiple boards including Halozyme Therapeutics (NASDAQ: HALO), Talis Biomedical (NASDAQ: TLIS) and Stemson Therapeutic, and as Chairman of the Board of Nautilus Biotechnology (NASDAQ: NAUT). He holds a bachelor’s degree in management science from UC San Diego.
Mr. Capone is an accomplished life sciences executive, most recently serving as president and chief executive officer of Myriad Genetics which he transformed from a pioneering start-up to one of the largest precision medicine companies in the world. During his 17-year tenure, Myriad Genetics developed and launched more than a dozen reimbursed molecular diagnostics achieving total annual revenues of more than $800 million. Prior to Myriad, he spent 17-years at Eli Lilly and Company in various leadership positions. Mr. Capone currently serves as chief executive officer of Precision Medicine Advisors, LLC, and is a non-executive board member of Abcam plc and Owlstone Medical. He received a B.S. in Chemical Engineering from Penn State University graduating with highest distinction, and his M.S. in Chemical Engineering (biotechnology emphasis) and Management from Massachusetts Institute of Technology.
President and CEO
Bret Christensen has served as the President, CEO and a director of the DermTech board since May 2023. Prior to joining DermTech, Mr. Christensen was the Chief Commercial Officer of Insulet from May 2017 to May 2023 where he oversaw sales growth from approximately $367 million to $1.1 billion. Mr. Christensen has demonstrated success in successfully scaling novel diagnostic companies and securing reimbursement with various types of payers. From August 2013 to May 2017, Mr. Christensen served as general manager of Preventive Care at Myriad Genetics, Inc. Prior to Myriad Genetics, Mr. Christensen held several executive positions at Hologic, Inc., including vice president of sales and marketing of its Gynecologic Surgical Products division. Prior to Hologic, Mr. Christensen led key market development and sales teams at Cytyc Corporation. Mr. Christensen earned a B.S. in Business Management from Utah Valley University and an MBA from the University of Utah.
Cynthia Collins has served on our board of directors since the completion of the Business Combination in August 2019 and on DermTech Operations’ board of directors between July 2018 and August 2019. Ms. Collins served as Chief Executive Officer of Editas Medicine, Inc. (Nasdaq:EDIT) from March 2019 to February 2021 and served as a member of the board of directors of Editas Medicine from December 2018 to February 2021. Ms. Collins served as Chief Executive Officer of Human Longevity Inc. from January 2017 to December 2017. From October 2013 to December 2016, Ms. Collins served as the Chief Executive Officer/General Manager of General Electric’s Healthcare Cell Therapy and Lab Businesses and GE’s Clarient Diagnostics. Prior to GE, Ms. Collins served as CEO of GenVec (NASDAQ:GNVC), a vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses. Prior to Beckman Coulter, she served as CEO of Sequoia Pharmaceuticals, Inc., a company developing HIV and HCV therapeutics. Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA from The University of Chicago Booth School of Business. Ms. Collins is a member of the board of directors of ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics, and Biocare Medical. Ms. Collins is qualified to serve on our board of directors because of her broad experience serving as the chief executive officer for a variety of companies in the life sciences industry and her experience serving on numerous boards of directors.
Nathalie Gerschtein brings over 20 years’ experience in international marketing, brand development, business strategy and general management at L’Oréal, the world’s leading beauty company. Nathalie has led a variety of businesses within the L’Oréal Group across Europe, Asia and the United States and played a pivotal role in transforming the beauty industry.
Since March 2019, Ms. Gerschtein has held the role of President of the Consumer Products Division in the United States, the largest division in L’Oréal Group’s #1 subsidiary. Ms. Gerschtein is responsible for accelerating growth, innovation, and sustainable practices across its mass market portfolio of brands and product categories from skin care and makeup to hair care and color. This extensive portfolio includes some of the most trusted and iconic brands such as L’Oréal Paris, Maybelline New York, Garnier, and NYX Professional Makeup, in addition to Essie, Thayer’s Natural Remedies, Carol’s Daughter, and Softsheen-Carson. In her current role, Ms. Gerschtein leads thousands of diverse and talented L’Oréal employees who are passionate about embodying L’Oréal’s global purpose: to create the beauty that moves the world. She is the first woman to lead L’Oréal USA’s Consumer Products Division.
Through an appointment by the French Prime Minister, Ms. Gerschtein serves on the board of the French Foreign Trade Advisors. She is a graduate of HEC School of Management in Paris, the London Business School, and INSEAD’s senior executive leadership program.
Dr. Kirk Malloy
Dr. Malloy has spent over 25 years in key leadership positions with Illumina, Inc., Biosite Inc. and QIAGEN Inc., and most recently served as the chief executive officer of Verogen, Inc., from August 2017 to August 2018 after founding the company and securing initial funding. Dr. Malloy is currently founder and principal at BioAdvisors, LLC, where he provides strategic consulting services to life science, diagnostics and genomics companies. Prior to founding BioAdvisors in April 2016, he was at Illumina, Inc. from 2002 to 2016, most recently as senior vice president and general manager of Life Sciences and Applied Markets from January 2014 to April 2016. From May 2005 to December 2013, he served as vice president of Global Customer Solutions; he was also vice president of Global Quality from December 2005 to May 2007. Dr. Malloy joined Illumina in 2002 as senior director of Global Customer Solutions. Before Illumina, he held various commercial leadership positions at Biosite Inc. and QIAGEN Inc. Dr. Malloy currently serves as chairman for Rapid Micro Biosystems (NASDAQ: RPID), a director for NanoString Technologies, Inc. (NASDAQ: NSTG), as chairman for cancer diagnostics company, Tagomics, and is a director for several private genomics tools companies. Dr. Malloy earned his B.S. in Biology from the University of Miami, and his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University.
Herm Rosenman brings more than 30 years of public company operating and financial experience. Mr. Rosenman has served as a member of the board of directors of Natera, Inc. since 2017, and as its CFO from 2014 to 2017. Prior to that, he was the SVP of finance and CFO of Gen-Probe Inc., where he was instrumental in its 2002 IPO and its 2012 sale to Hologic Inc. Prior to joining Gen-Probe, Mr. Rosenman was president and CEO of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, and president and CEO of RadNet Management Inc., a large healthcare provider. From 2012 to 2014, Mr. Rosenman focused on his board memberships. He has served on the board of directors of Oxford Immunotec Global PLC, a commercial-stage diagnostics company, since 2013, and of Vivus, Inc., a biopharmaceutical company, also since 2013. Mr. Rosenman also previously served on the board of directors of BioFire Diagnostics, Medistem, Inc., a stem cell therapy company, ARYx Therapeutics Inc., a private drug discovery and development company, Infinity Pharmaceuticals, Inc., a drug discovery and development company, and several privately held companies. Mr. Rosenman holds a BBA in accounting and finance from Pace University and an MBA in finance from the Wharton School of the University of Pennsylvania.